Surgical wound infiltration with liposomal bupivacaine admixture as an adjunct to intrathecal morphine for post-caesarean analgesia: a randomised, double-blind controlled trial.
Abstract
Background
Intrathecal morphine is the gold standard for post-caesarean analgesia, but it lasts only 18-24 h. Whether wound infiltration adds benefit in patients receiving intrathecal morphine remains controversial. This study evaluated the opioid-sparing efficacy of wound infiltration with a liposomal bupivacaine-bupivacaine hydrochloride admixture as an adjunct to intrathecal morphine.
Methods
In this double-blind, placebo-controlled trial, 188 patients undergoing elective caesarean delivery with intrathecal morphine (100 μg) received either wound infiltration with liposomal bupivacaine (266 mg) plus bupivacaine hydrochloride (100 mg), or saline placebo. All patients received standardised multimodal analgesia including scheduled non-opioid analgesics and hydromorphone patient-controlled analgesia. The primary outcome was cumulative opioid consumption (oral morphine milligram equivalents) at 48 h.
Results
With treatment, 48-h opioid consumption was significantly lower (12.60 mg [IQR 6.30-15.80] vs. 15.75 mg [IQR 9.45-25.50]; Hodges-Lehmann estimate -3.05 mg, 95% CI -5.9 to -1.4; P = 0.002). Secondary outcomes also favoured treatment: 24-h opioid consumption (6.30 vs. 9.45 mg; P < 0.001), movement-evoked pain at 24 h (40 vs. 50 mm; P < 0.001) and 48 h (30 vs. 40 mm; P < 0.001), time to first analgesic request (14.5 vs. 9.5 h; P < 0.001), and opioid-free status at 48 h (19.1% vs. 2.1%; RR 9.0; 95% CI 2.1-37.8; P < 0.001).
Conclusions
In women undergoing scheduled caesarean delivery, wound infiltration with a liposomal bupivacaine-bupivacaine hydrochloride admixture significantly reduced postoperative opioid consumption and improved pain scores. It may be an effective opioid-sparing adjunct to intrathecal morphine.